INTRODUCTION
Endometriosis is a common estrogen-dependent gynecological disease defined as the presence of endometrial tissue outside of the uterus in lesions containing endometrial glands and stroma. The prevalence has been estimated at 5%-10% for women of reproductive age in the general population and between 35% and 50% for women with chronic pelvic pain and subfertility [1] . The disease may be asymptomatic or associated with severe pelvic pain and subfertility [2] .
Endometriosis is a complex disorder influenced by multiple genetic and environmental factors. The contribution of genetic variation to endometriosis risk is well established from both clinic-and population-based samples [3, 4] . Based on a study of 3096 twins, the proportion of disease variance due to genetic factors (heritability) was estimated at 51% [5] . Once the role for genetic variation was established, it paved the way for efforts to identify the genetic factors responsible. Initial studies focused on classical genetic linkage and candidate gene studies. These were not successful, and possible reasons for this have been reviewed elsewhere [3, 4] . More recently, genome-wide association studies (GWAS) using high-throughput genotyping have revolutionized gene discovery and our understanding of the genetic contributions to complex disease. Four GWAS of endometriosis have been reported [6] [7] [8] [9] , and at least 6 genomic regions show genome-wide associations following meta-analysis across multiple studies [10, 11] . The results are robust across populations and different ethnic groups.
Despite significant research efforts, the pathogenesis and evolution of endometriosis remain unclear, and treatment options are limited. Therefore, genomic regions contributing to disease risk represent an important breakthrough toward the goal of understanding the biological basis of the disease and future progress toward better diagnosis and treatment. However, identifying genomic regions associated with disease risk is only the first step. Further detailed research is required to identify the specific genes involved, determine the biological differences responsible for increased disease risk, and translate the new knowledge into better outcomes for patients.
As noted in recent international workshops on future directions in endometriosis research [12] , one of the major factors limiting progress is the need for multidisciplinary teams and collaborations to tackle the complex issues. This applies particularly to follow-up studies of genomic regions identified by GWAS. Success will require new collaborations between clinicians and scientists with expertise in genetics, genomics, disease biology, and specialized knowledge of genes and pathways identified to unravel the functional consequences and important mechanisms leading to disease.
This review describes the studies needed to follow-up significant GWAS results to identify these biological pathways responsible for disease. It is not intended as a general review of genetic and epigenetic studies in endometriosis as this has been covered elsewhere [3, 4, [13] [14] [15] . The review sets out the multiple steps required to interpret the genetic association results for endometriosis, identify the specific genes likely to be responsible for the altered risk within each region, and presents the necessary genomic evidence for connecting genetic results to target genes. The strategies ( Fig. 1 ) used include fine mapping and genotyping to better define the signals in each region, functional annotation (bioinformatics), genomics, and target gene identification through gene expression and epigenetic studies, cell-based studies defining direct interactions between causal single nucleotide polymorphisms (SNPs) and target genes, and ultimately, functional and clinical studies. Significant progress will require teams with an understanding of both genetics and disease biology, and this review is intended to provide a framework for these studies.
GENOMIC REGIONS ASSOCIATED WITH ENDOME-TRIOSIS RISK
There is robust evidence for genomic regions associated with endometriosis risk [10, 11] . These studies exploited significant advances in technology and knowledge of the human genome to genotype a representative set of SNPs chosen to ''tag'' all common variants in the genome, using array-based techniques. Cases and controls must be carefully matched for ethnicity. Analyses must include appropriate corrections for multiple testing, and results need to be replicated in independent samples. Applying these guidelines, there is excellent agreement among studies of genomic regions associated with endometriosis risk.
Published endometriosis GWAS include two studies in Japanese women [6, 9] and two in women of European ancestry [7, 8] and a meta-analysis of summary data [10] from the International Endogene Consortium study [8] and the larger Japanese study [9] . In addition, two replication studies of some of the key SNPs identified in the GWAS have been published [16, 17] . Results have been summarized [11, 18] , and a recent meta-analysis was conducted combining data from all of these studies [11] . There is excellent agreement across all studies for the major regions implicated in endometriosis risk. Six regions show evidence of significant genome-wide association in all cases or severe cases or both groups (Table 1) and results for the region around fibronectin 1 (FN1) are close to genomewide significance, with the strongest evidence in severe cases [11] . Recently, a meta-analysis of GWAS and replication studies confirmed associations between endometriosis risk and SNPs in the region of interleukin-1A (IL1A) on chromosome 2 [19] , adding a further important region for follow-up.
GWAS RESULTS DEFINE GENOMIC REGIONS ASSOCI-ATED WITH ENDOMETIOSIS RISK
GWAS ''hits'' define a region of the genome associated with endometriosis, as the association comes from analysis of representative tagged SNPs. The causal variant(s) could be any of the tagged variants (see below). Functional validation and characterization of the many genes within GWAS ''hits'' is challenging. It is often confined to single-gene approaches and frequently to plausible candidate genes selected based on their proximity to sentinel SNPs. There are highly plausible candidate genes in several of the genomic regions associated with disease risk, including the growth regulation by estrogen in breast cancer 1 (GREB1) gene, the homeobox A gene cluster, WNT4, and ID4. GREB1 was first identified in breast cancer cell lines and tumors [20] and is regulated by estrogen receptor a (ERa) through estrogen response elements (EREs) located ;20 kb upstream of the gene [21, 22] . Knockdown of GREB1 inhibits estrogen-induced growth in the MCF-7 breast cancer cell line [23] , and differential expression of GREB1 (mRNA and protein) has been reported in endometriosis, with expression that is increased in cases of women with ectopic endometrial lesions and eutopic endometrium compared to that in control women [24] .
The intergenic SNP rs12700667 on chromosome 7 lies upstream of the homeobox A family gene cluster, including homeobox A10 (HOXA10) and homeobox A11 (HOXA11), transcription factors that play important roles in uterine development [25, 26] . HOXA10 may also be involved in regulation of embryo implantation and aspects of endometriosis [27] . Women with endometriosis do not demonstrate the expected mid-luteal rise of HOXA10 expression, which might 
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partially explain the infertility observed in many of these patients.
On chromosome 1, the wingless-type MMTV integration site family, member 4 (WNT4) gene is critical for development of the female reproductive tract [28, 29] . WNT4 and other WNT family members are expressed in human endometrium during both the proliferative and the secretory phases of the menstrual cycle [30] . Expression is upregulated by estrogen in an estrogen receptor-independent manner [31] , and Wnt signaling is important for epithelial-stromal cell communication in the endometrium [32] . The signal on chromosome 6 is located 52 kb from the inhibitor of DNA binding 4 (ID4) gene, which is overexpressed in most primary ovarian cancers but not in normal ovaries, fallopian tubes, and other tissues. Hypermethylation of several tumor suppressor genes including ID4 is an early event in the development of breast cancer [33] and small interfering RNA (siRNA) knockdown in mice bearing ovarian tumors suppressed growth of established tumors and significantly improved survival [34] .
These plausible candidates need to be fully evaluated, but the genetic mapping data defines only the region of the genome associated with disease risk. Critical regions generally include a large number of genes, and GWAS have uncovered many unexpected genes and pathways implicating novel disease mechanisms. Follow-up studies should evaluate all genes in these regions to determine the functional changes responsible for the increased disease risk.
For example, the region of strong association on chromosome 1 near WNT4 (Fig. 2) extends across the adjacent genes cell division control protein 42 (CDC42) and long intergenic non-protein coding RNA 339 (LINC00339) [7, 10] . Both CDC42 and noncoding LINC00339 RNA (also known as HSPC157) are expressed in endometrium and have been implicated as contributors to endometriosis. CDC42, a small GTPase of the rho subfamily, is differentially expressed in endometriosis [35] and involved in signaling pathways that control diverse cellular functions including cell morphology, migration, endocytosis, and cell cycle progression. LINC00339 is also differentially expressed in endometriosis lesions compared with eutopic endometrium [36] .
In the chromosome 7 region, HOXA10 and HOXA11 are located 1.35 Mb downstream from the key SNP rs12700667. The closest gene, nuclear factor (erythroid-derived 2-like 3) (NFE2L3), is a transcription factor thought to be involved in cell differentiation, inflammation, and carcinogenesis [37] . NFE2L3 mRNA levels were found to be upregulated in human breast cancer cells [38] and testicular carcinoma tissue samples [39] . Systematic studies need to be applied to screen the many genes within each region and find the causal variants driving the biological differences.
INTERPRETING ASSOCIATION SIGNALS
Defining the molecular mechanisms for each genomic region associated with endometriosis risk is a major challenge [18, 40, 41] . SNP variations could influence disease risk through a number of mechanisms including changes in protein sequence, transcript stability, gene expression (through modifying promoter, enhancer, or insulator sequences), or modification of other transcripts such as micro-RNAs or long noncoding RNAs affecting target genes elsewhere in the genome. Understanding how SNP variation is translated into altered disease biology and which genes are implicated will require combined studies of genetics, genomics, and cell biology.
Despite the challenges, robust evidence for genomic regions influencing endometriosis provides a major advance with the potential to unlock underlying biology and contribute to TABLE 1. Genetic variants underlying risk of endometriosis from meta-analysis of eight genome-wide association and replication datasets [11, 19] . Genetic association between markers on chromosome 1 and endometriosis risk in combined European and Japanese samples, together with genes in the region shown in the bottom panel (LINC00339 is represented by the alternative name HSPC157) (adapted from Nyholt et al. [10] ). The strength of the association signals for individual SNPs is plotted on the Y-axis (circles and diamonds are Àlog10 P values) relative to their location on chromosome 1. The red circle identifies SNP rs7521902 (purple diamond), identified as the best signal in the genome scans of Japanese and European women [8, 9] . This SNP is located ;20 kb upstream of the promoter for WNT4. Following imputation of all SNPs across the region, a number of additional SNPs within the orange ellipse showed stronger association signals and spanned a region from intron 1 of WNT4 across the adjacent genes CDC42 and LINC00339.
SNP
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improved treatment outcomes. Despite the relatively recent advent of GWAS (the first GWAS was published in 2005), results are generating new biological insights, clinical outcomes, and novel science [42] [43] [44] . Examples include the importance of the autophagy pathway in Crohn's disease, the IL-23 receptor pathway in rheumatoid arthritis, initiation of therapeutic trials for target genes in multiple sclerosis and rheumatoid arthritis, and new insights into human population structure and evolution [42] [43] [44] . One example of clinical application is the new clinical guidelines published for managing simvastatin-induced myopathy, an adverse side effect in patients treated with statins including simvastatin [42] . In this case, GWAS identified a common variant in the solute carrier organic anion transporter 1B1 (SLCO1B1) gene, which causes a 4.5-fold increased risk of myopathy by reducing hepatic uptake and increasing serum concentrations [42] . More generally, genes implicated by GWAS are significantly more likely to be targets for existing drugs or biopharmaceuticals, and matching GWAS traits and drug indications suggests important opportunities for drug repositioning [45] .
Multiple Correlated SNPs Show Similar Disease Association Signals
One of the first issues is to determine the size of each region to be considered in the search for both the causal SNP(s) and the target genes. The size of the region is influenced by correlations between SNPs in local genomic regions. Genomic regions influencing endometriosis generally contain many different SNPs with equivalent evidence for association and span multiple genes. This was illustrated for the chromosome 1 region (Fig. 2) . The strength of the association signals for individual SNPs is plotted on the Y-axis (circles and diamonds as Àlog10 P values) relative to their location on chromosome 1 and identifies a large block of correlated SNPs associated with endometriosis risk that extends from LINC00339 to WNT4.
The blocks of SNPs associated with disease risk result from patterns of variation in the genome in modern humans following recent evolution. Large-scale SNP genotyping and sequencing studies show that, on the scale of the genomic regions linked to disease risk, genotypes of SNPs near each other are strongly correlated across individuals [46, 47] . These correlated SNPs are said to be in linkage disequilibrium (LD). The correlation patterns for SNPs close to each other show structure with organization in blocks of ;200 kb separated by ''hot spots'' of recombination [46, 48, 49] where correlations between adjacent SNPs break down. The pattern of multiple SNPs associated with endometriosis risk on chromosome 1 (Fig. 2) represents one of these blocks, and other regions show similar patterns with blocks of correlated SNPs associated with disease [7, 10] .
These patterns of LD in the human genome have important practical applications. They provided the basis for large-scale GWAS by defining a set of representative tagged SNPs for genotyping that capture signals from most common variation in the genome. They also make it possible to infer or impute genotypes for an individual for common SNPs in the genome by combining data from GWAS genotypes and a reference panel of densely genotyped or sequenced samples [43] . However, LD patterns that helped in gene discovery make the next steps of tracking down the causal variant(s) more challenging. The causal variant(s) will likely be on the list of associated SNPs, but it is difficult to determine which among them is responsible for the increased disease risk. It is common to define the SNP with strongest association signal as the sentinel SNP. In most cases, the sentinel SNP will not be the causal variant itself but will be correlated with the functional variant(s) elsewhere within the region.
Long-range Effects of SNP Variation in Regulatory Sequences
The LD regions associated with endometriosis risk [10, 11] vary in size from 40 to 170 kb. However, the region of LD only defines the likely region for the location of the causal SNP. A second consideration is the potential long-range effects of causal (functional) SNPs located in DNA sequences with longrange effects on gene expression (Figs. 3 and 4) . Because most of the GWAS signals have yet to be decoded, we do not know the patterns of regulatory elements involved and the average distance between the causal variant and gene or genes affected.
It is likely that GWAS signals influence expression levels of a gene or genes in the immediate region. In this regard, studies of the genetics of gene expression are informative (Fig. 1) . DNA sequence variations can influence the expression of individual genes, and these are known as expression quantitative trait loci (eQTLs). These variations can be located at the gene promoter or within long-range enhancers that affect gene expression [40] . We and others have shown that most eQTL SNPs are located near the transcription start sites of the target gene [50] . However, eQTL SNPs can be located up to 2 Mb upstream or downstream from the target gene [50] . Therefore, we may have to search up to 4 Mb around each sentinel SNP to identify the causal variants and the target genes in each region.
Regulatory SNPs Can Be Located Outside of Target Genes
As noted above, most GWAS signals are located outside of gene coding regions, and the causal SNP may be located in a regulatory sequence 2 Mb from the target gene. There are few examples where the causal SNP, regulatory sequence, and target gene have all been identified. One example is the regulation of blue or brown eye color. A major eye color locus was mapped to chromosome 15 in the region of the oculocutaneous albinism II (OCA2) gene [51] . Fine mapping studies genotyping all common SNPs in the region identified a single SNP, rs12913832 [52] , which accounted for 95% of the variation in blue/brown eye color (Fig. 3) . This SNPs is located 21 kb upstream of OCA2 within an intron of the adjacent gene, HECT, and RLD domain containing E3 ubiquitin protein ligase 2 (HERC2). Although it is located in an intron of HERC2, the target gene is OCA2, because rs12913832 alters an enhancer regulating OCA2 transcription [53] . Chromosome conformation capture (3C) analysis showed a marked decrease in interaction frequency between the enhancer and the OCA2 promoter for the blue eye variant [53] . There is also reduced recruitment for the transcription factors helicase-like transcription factor (HLTF), lymphoid enhancer-binding factor 1 (LEF1), and microphthalmia-associated transcription factor (MITF) at the sequence for the blue eye allele [53] . Although the causal variants identified by GWAS have smaller effects, many will be located with regulatory elements in the genome and act through similar mechanisms.
FINE MAPPING
Once disease-associated regions have been identified and replicated in independent studies, further genetic studies are necessary to refine the association signal (Fig. 1) . The objectives of fine mapping are to narrow the region of association, identify the strongest signals, and determine whether there is more than one independent signal in each FUNG ET AL.
region. The best approach would be to genotype all SNPs across the critical regions in the greatest possible number of samples.
Developing custom chips for genotyping all SNPs across the current regions would be expensive and likely need to be repeated when further genetic studies identify new regions of association. An alternative to custom chips that genotype all SNPs in a region is to use imputation with follow-up genotyping of selected key SNPs. Imputation methods have been developed to estimate genotypes for common SNPs [18, 43] , by combining data from the backbone of GWAS SNPs in a sample with a reference set of individuals with complete genome sequence. Genotypes for all common SNPs can then be imputed (estimated) in the discovery sample. These methods are now widely used and are improving with the access to better reference sets of whole genome sequence data. The accuracy of imputation can be tested empirically by genotyping key SNPs. For example, imputation in endometriosis discovery populations identified a number of SNPs with stronger evidence of disease association than the SNPs genotyped on the chips [7, 10] . Results for the key SNPs located in intron 1 of WNT4 have been confirmed by genotyping these SNPs in a sample of ;900 cases with 98%-100% concordance between genotyped and imputed data [54] .
A second objective for fine mapping is to dissect the association signals in each region. Fine mapping and GWAS in large sample sizes have demonstrated that more than one independent signal exists in some regions. Conditional analysis including the top SNP is conducted following fine mapping or imputation in additional samples to evaluate evidence for independent signals that should also be followed. For example, a recent meta-analysis of GWAS data for age at menarche [55] identified 123 independent signals for age at menarche at 106 genomic regions. Eleven regions (10%) contained multiple independent signals.
Given the success of imputation and high cost of custom genotyping for several thousand SNPs, the best approach is to reserve limited funding for genotyping GWAS chips in new sample sets. This will provide improved power for both fine mapping and future gene discovery. Key imputed SNPs with the strongest signals or evidence of functional effects can be genotyped to verify the accuracy of imputation. This approach is being used for fine mapping in endometriosis [18, 54] .
TARGET GENE IDENTIFICATION
The translational value of GWAS in complex diseases lies in discovery of specific genes and biological pathways predisposing to the condition. An important discovery from GWAS is that the majority (.80%) of GWAS ''hits'' are located in noncoding (introns and intergenic) regions of the genome [56, 57] and are likely to exert their effects through gene regulation. Increasing evidence shows GWAS ''hits'' are often located in promoter, enhancer, or insulator sequences and are enriched for SNPs with effects on gene expression [58, 59] . This is also likely to be true for markers associated with endometriosis [10, 11] .
Our inability to easily identify target genes in GWAS loci has exposed big gaps in our knowledge of gene regulation. Thus, one of the major outcomes from GWAS is a re-energized , accounting for 95% of the variation in blue or brown eye color is located in an enhancer-regulating OCA2 transcription [53] . A) Map of the region showing OCA2 and HERC2 and the location of rs12913832. B) Effects of different alleles of rs12913832 on blue/brown eye color. C) SNP rs12913832 is located in a highly conserved sequence, and the C (blue) allele reduces recruitment for the transcription factors HLTF, LEF1 and MITF and shows a marked decrease in interaction frequency between the enhancer and the OCA2 promoter for the blue eye variant [53] .
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international effort toward a better basic understanding of gene regulation in humans. International studies such as the Encyclopedia of DNA Elements (ENCODE) project [60] have demonstrated that these noncoding regions contain many regulatory sequences that control where and when specific genes are expressed to make proteins. It is likely that most functional variants responsible for increased endometriosis risk will not alter individual proteins but will be located within regulatory elements in the genome. We expect the alternative alleles will change the relative levels, timing, or tissue specificity of gene expression and/or relative expression of different splice variants and isoforms of RNA and proteins. Fortunately, recent technical and conceptual advances have helped to develop more systematic approaches to identify the target genes linked to endometriosis-associated SNPs (Fig. 1 ) [40, 41] .
Functional Annotation of Genomic Regions Associated with Endometriosis
Putative functional effects for key SNPs identified from fine mapping can be assessed using a range of public databases and 
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bioinformatics tools (Fig. 1) . SNPs that disrupt coding sequences of genes can be evaluated with a number of programs that assess amino acid substitutions [61] [62] [63] [64] . SNPs in the 3 0 -untranslated region (3 0 -UTR) can be screened for their potential to change micro-RNA-binding sites using miRBase [65] , miRDB [66] , and MicroInspector databases [67] .
Where sentinel SNPs are located in regulatory regions, the potential role of these SNPs (together with correlated SNPs in moderate to strong LD with these lead SNPs) can be evaluated using annotation tracks of functional elements from a tissue or cell type relevant to endometriosis (Fig. 4) , derived from the international ENCODE project, designed to characterize functional elements in the genome [60] and related studies. Systematic whole-genome assays such as RNA-seq, ChIP-seq, DNase-seq, FAIRE-seq, and Repli-seq identify functional elements and regulatory regions for transcription factor-binding sites, chromatin structure, and histone modification in a range of cell lines [60] . These data are available in genome browsers and can be used to search for the overlap between diseaseassociated variants and functional elements to prioritize SNPs for follow-up functional studies.
Bioinformatics tools [46, 59] integrate data from public databases to help functional annotation of lead SNPs. They include tools to identify genetic variants that significantly alter DNA recognition motifs such as RegulomeDB [68] , HaploReg [69] , FunSNP [70] , and SnpEff [71] . The programs test effects of individual SNP variation on genomic features, including gene and isoform annotations, eQTL, chromatin immunoprecipitation sequencing (ChIP-seq), DNase I hypersensitive sites (DHS), chromatin interactions, evolutionary sequence conservation, and transcription factor binding sites.
Functional annotation of lead SNPs can be combined with fine mapping results to prioritize SNPs for follow-up studies. However, annotations relying on the data available in projects like ENCODE have limitations. There is a high risk that analyses will produce both false positive and false negative results. The programs may report false positives, identifying SNPs in regulatory sequences from cell types that are not relevant to the disease. Conversely, false negatives arise because, as noted elsewhere, cell lines from reproductive tissues are under-represented in genome-wide studies of regulatory sequences [57] .
Following fine mapping in the WNT4 region on chromosome 1, we conducted functional annotation of the top 50 SNPs with lowest P values by using HaploReg and RegulomeDB [54] . Three top variants (rs12404660, rs3820282, and rs55938609) had evidence for potential functional effects and were located in validated and significant regions of open chromatin with binding sites for the transcription factors FOXA1, FOXA2, and estrogen receptor (ESR1) [54] . Breast cancer risk variants preferentially target enhancers bound by the transcription factors FOXA1 and ESR1 within breast cancer cells [72] . Given the fact that endometriosis is an estrogen-dependent disease, the functional annotation of lead SNPs to enhancers bound by FOXA1 and ESR1 is intriguing and suggests ENCODE data from breast cancer cell lines may be relevant to functional annotation of genomic regions associated with endometriosis. However, any role of these key SNPs in regulating expression of WNT4 or adjacent genes relevant to endometriosis risk has yet to be demonstrated.
Linking Genetic Variation and Gene Expression
Experimental approaches include analysis of whether the sentinel SNP or correlated SNPs affect the expression of genes in the region through eQTL studies (Figs. 1 and 4) . Several eQTL studies combining gene expression and genotype data have shown that many disease-predisposing variants affect expression levels of genes in the local region [73, 74] . One model is that SNPs in regulatory sequences (in enhancers or promoters) alter the strength of binding sites for transcription factors and influence rates of gene transcription (Fig. 4B) . Variants affecting expression of nearby genes are defined as cis-eQTLs, and a recent eQTL meta-analysis in 5311 peripheral blood samples from 7 studies identified cis-eQTLs for .40% of all genes tested [75] . As noted above, most cis-eQTL are located close to the transcription start site for the target gene, but some can be located as far as 2 Mb from the transcription start site [50] .
In addition to cis-eQTL effects, SNPs can influence expression of genes on different chromosomes (i.e., transeQTLs). These are more difficult to detect because a large number of tests are conducted to search all genes relative to genome-wide SNP data, and stringent multiple testing thresholds must be applied. Published meta-analyses of gene expression in blood from ;5000 individuals analyzed 2082 SNPs previously associated with complex traits at genomewide significance (P , 5 3 10 À8 ; [75] ) and detected 1340 significant trans-eQTL that included 254 unique SNPs (12% of all SNPs tested) [75] . Results for 233 SNPs were replicated in independent samples.
Disease-associated SNPs affecting expression of genes on other chromosomes (trans-eQTLs) also affected the expression levels of nearby transcription factors in cis. The data suggest that some trans-eQTLs arise due to altered cis gene expression of nearby transcription factors [75] . The trans-eQTL SNPs and correlated SNPs are also significantly enriched for mapping within micro-RNA binding sites.
Listed trans-eQTLs in blood for lipid-regulatory and immune-mediated disease variants yields valuable insights into biologically meaningful downstream pathways [75] . For example, SNP rs174546 (located in the 3 0 -UTR of FADS1 and associated with low-density lipoprotein [LDL] and total cholesterol levels) affected expression levels of the TMEM258, FADS1, and FADS2 genes in cis and the expression of LDL receptor (LDLR) in trans [75] . LDLR contains common variants that are also associated with lipid levels and LDLR expression is negatively correlated with high-density lipoprotein (HDL) and LDL cholesterol levels. Some SNPs affected multiple genes in trans that are altered in individuals with disease. For example, rs4917014, previously associated with systemic lupus erythematosus, altered gene expression of C1QB and five type I interferon response genes, both of which are hallmarks of systemic lupus erythematosus. Comprehensive and well-powered studies of gene expression regulation in the endometrium and other relevant tissues would greatly help to decode GWAS ''hits'' affecting endometriosis and other reproductive diseases.
Genetic Variations and Epigenetic Changes
Endometriosis SNPs may also affect gene expression through effects on DNA methylation and modifications to the histone proteins associated with DNA packaging in chromatin. These modifications, including methylation, acetylation, and phosphorylation, affect chromatin structure and subsequent transcription of genes in the immediate region. Until recently, epigenetic mechanisms were thought to be independent of the DNA variation among individuals [76] . However, a series of recent papers has demonstrated that underlying DNA sequence differences influence differences among individuals in both methylation patterns and histone modification [77] [78] [79] [80] .
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Methylation patterns in DNA from peripheral blood leukocytes from the HumanMethylation450 array (Illumina) in samples from 614 individuals from 117 families [79] demonstrated that SNP variation affects the strength of methylation signals at many sites in the genome. Approximately 20% of the variation in methylation signals are attributed to genetic effects (heritability ¼ 0.19) and ;80% environmental effects [79] . Consequently, GWAS ''hits'' in endometriosis may also affect disease through effects of causal SNPs on methylation (mQTL) of promoters or other regulatory sequences. For example, top ''hits'' from GWAS in bipolar disorder [81] are associated with both cerebellar expression and methylation, but there is limited overlap of eQTL and mQTL affecting the same gene. Comparisons of methylation patterns in ovarian endometrial stromal cells and healthy endometrial stromal cells [82] reported differential methylation for several genes in the endometriosis-associated regions identified by GWAS including GREB1, CDKN2BAS, and VEZT, but it is not known whether these methylation patterns are influenced by local SNP variation. These results highlight the importance of integrating functional annotation of genetic variants for gene expression and DNA methylation to advance the biological understanding of disease traits.
Histone modifications are also under genetic control, with genetic variation affecting both epigenetic signals and gene regulation [76, 80, 83] . It is likely that genetic effects on histone modification and gene regulation are mediated by altered transcription factor binding [76] . One model proposes that disease-associated variants affect the recruitment and binding of transcription factors to DNA influencing local gene expression (cis-eQTLs) with downstream effects on expression of genes on other chromosomes (trans-eQTLs) altering gene pathways [75] . However, many DNA variants that affect both epigenetic marks and transcription factor binding are not associated with obvious changes in gene expression [77, 80, 83] .
Connecting SNP Function to Target Genes: Chromatin Conformation Capture
Many disease-associated SNPs are located at intergenic regions where the causal variants are likely to be located in cis regulatory elements such as promoters, enhancers, and insulators affecting genes that can be located some distance away (Figs. 1 and 4) [78, 84] . The most frequent elements affected are transcriptional enhancers and silencers. These elements are typically located more than 1 kb from their target genes and regulate transcription through long-range interactions mediated by the formation of chromatin loops [85] . Bioinformatics and eQTL studies can help identify functional SNPs and target genes. However, it is important to determine the functional connection between target genes and regulatory elements and confirm causation. Development of the 3C method provides a powerful way to map these interactions [86] by determining physical interactions between them.
The 3C and related methods are used to study intracellular DNA organization. The three-dimensional structure of the chromatin is captured by formaldehyde cross-linking in living cells. This ensures the regions that are in contact are chemically fixed. The chromatin structure is digested into DNA fragments with restriction enzymes and then ligated to obtain a 3C template. The final step of the 3C method consists of measuring the relative abundance of individual purified ligation products in the library. 3C library products are usually quantified by PCR amplification of ligation junctions with agarose gel detection of DNA products. Alternatively, ligation junctions can be measured by TaqMan quantitative PCR and melting curve analysis [86] [87] [88] .
The 3C technique has been used to identify target genes of regulatory variants from GWAS. 3C studies in breast cancer cells have demonstrated that strong association signals for breast cancer risk in the 11q13 and 10q26 regions map to transcriptional enhancers. These enhancer regions distally regulate the CCND1 [89] and FGFR2 promoters [90] , respectively. Once target genes have been implicated in endometriosis, 3C experiments will be required to identify the causal variants and transcriptional enhancer elements.
It has been suggested that genetic variants located in regulatory elements might influence the activation of multiple promoters and, therefore, directly affect the expression of more than one gene. A recent study in prostate cancer cells has shown that the variants at the 8q24 prostate cancer risk locus exhibit minimal RNA transcript output but contain regulatory elements, especially enhancers [91] . Multiple cis effects of the 8q24 risk locus were identified and showed interaction with the MYC promoter and the PVT1, FAM82B, and GSDMC genes at the 8q24 locus. Frequent trans interaction has also been observed, where the strongest long-range interaction was with CD96 at locus 3q13 [91] . Although 3C is a powerful method for providing evidence of chromatin interactions at disease risk loci, the choice of cell type is also important because regulatory elements are highly tissue-and cell-type specific.
TISSUE-SPECIFIC EXPRESSION AND TARGET GENE IDENTIFICATION IN ENDOMETRIOSIS
Taken together, the studies reviewed above demonstrate complex interactions among genotype (DNA sequence variation), epigenetics, and gene transcription. In addition, tissuespecific and developmental differences in regulation of gene expression are further complicating factors [92] . Although many cis-eQTLs are observed across tissues, approximately 30% of cis-eQTLs are tissue-specific [92] . This has important consequences because we need to study gene expression in tissues relevant to the disease. To date, most studies with sufficient scale have been conducted using samples from blood or lymphoblastoid cell lines, although this is changing.
We do not know which tissue(s) and cell type(s) are targets for regulatory effects of SNP variation that increase endometriosis risk. Tissues contributing to the development and growth of endometriosis lesions could include deposition of viable endometrial tissue or endometrial stem cells via retrograde menstruation [93] [94] [95] , epithelial cells from the fallopian tubes [96] , embryonic cell rests [97] , mesothelium [98] , and the immune system [99] . It is also possible that the tissue of origin may vary for different presentations of endometriosis.
Data for relevant cell lines for reproductive tissues in the ENCODE project are limited, and comprehensive data that map critical regulatory sequences in reproductive tissues are not currently available. This limits our ability to rapidly link the SNP variation to target genes. We have initiated the Endometrial Gene Expression Project (EGEP) for eQTL studies in endometrium to help prioritize genes and pathways for follow-up studies. We chose endometrium for these studies as one important tissue in which we can examine regulatory effects of SNP variation affecting endometriosis.
Large sample sizes will be essential to have sufficient power to evaluate important tissue-specific regulation of gene expression. The effect sizes of eQTL are large compared with results for GWAS. However, our ability to significantly detect eQTL is also limited by the increased multiple testing burden FUNG ET AL. that is a feature of eQTL analyses. Power calculations show that a sample size of 100 tissue samples is required to detect an eQTL that explains ;10% of the variance in gene expression with 80% power (at a study-wide corrected P value of 10 À9 ). Increasing the sample size to 400 individuals at the same type I error rate (10 À9 ) and power (80%), we could detect eQTLs that explain ;6.3% of the variance in gene expression. Because the distribution of effect sizes is not uniform, and based on our data for whole blood, increasing sample size from 100 to 400 would translate to an increase in the numbers of eQTL detected from ;1200 with .10% variance to ;3100 with .6.3% variance. Given the fact that gene expression of endometrium varies throughout the menstrual cycle, even larger sample sizes with well-defined stage of menstrual cycle will be required to understand gene regulation in the endometrium and effects of the stage of the menstrual cycle.
FUNCTIONAL STUDIES
Predictions of the target genes from functional annotations, eQTL studies, and 3C experiments will require functional validation in appropriate model systems. Finding the appropriate in vitro and in vivo model systems is a challenge, especially in endometriosis research. Well-characterized cell lines can be used for functional assays to evaluate changes in gene expression, transcription factor recruitment, or cell proliferation/differentiation. However, many cellular responses, such as cell proliferation, differentiation efficiency, or drug response, cannot be assessed in an allele-specific manner, and results for specific risk genotypes need to be confirmed with cell lines homozygous for the alternative alleles. It will be important to control for overall genetic background in these cell lines because, as discussed above, there are large effects of background genetic variation on gene expression and epigenetic regulation. In this context, genetic background includes both the known endometriosis risk variants from all genomic regions and general genetic background for variants affecting target genes of interest.
Development of newer genome-editing technologies using the clustered, regularly interspaced, short palindromic repeats/ C-associated (CRISPRCas) genes can be used to artificially generate variant cell lines or mouse models of genetic risk variants by introducing mutations into the genome [100, 101] . Genome editing could be used to engineer sequence changes in cell lines with existing risk variants or generate lines with the appropriate risk alleles. Suitable animal models to study effects of genetic variation on endometriosis can be problematic because of the nature of the disease. No single-model system is ideal, but various in vivo models exist. They will need to be carefully selected to ensure the models are relevant to the specific gene pathways and research questions. In addition, a large proportion of the functional human genome is not conserved across species. Despite the limitations, functional studies to confirm results from in silico and eQTL studies will be essential in different tissues and under different physiological conditions. The most appropriate model systems will depend on the nature of the genes and pathways uncovered in the GWAS follow-up studies.
SUMMARY AND FUTURE PERSPECTIVES
GWAS have identified eight genomic regions with strong evidence for association with endometriosis risk and excellent replication in multiple studies. The results represent a significant breakthrough toward understanding endometriosis. Associated DNA sequence variation in these regions must be linked to the altered regulation and/or function of specific genes and pathways modifying endometriosis risk to make further progress. Capitalizing on the GWAS findings to help unlock the biological basis of the disease will require multidisciplinary projects and greater understanding of detailed gene regulation in relevant reproductive tissues.
There are attractive candidate genes in several of the associated regions. We may be surprised to find the genetic variation indeed targets the mostly likely candidate in a few regions. However, GWAS results for other complex diseases have highlighted major gaps in our knowledge about gene regulation. Most GWAS signals are located outside of gene coding regions and are thought to increase disease risk by modifying gene regulation. There will be multiple independent signals in some regions and regulatory variation might target multiple local genes and/or downstream pathways. It will be critical to provide strong evidence linking causal variants and gene targets to underpin the translational research needed to develop new treatments.
Identifying causal variants and interpreting the functional consequences of sequence variation in noncoding regions of the genome is challenging. The regulation of gene expression is complex with the expression of many genes influenced by SNP variation in promoters and enhancers and the indirect effects of SNP variation on epigenetic marks. Much of this variation is tissue specific. Fortunately, technical and conceptual advances are helping to develop more systematic approaches to address the functional mechanisms linked to common diseases such as endometriosis. Valuable insights into regulatory sequences in noncoding parts of the genome have come from international initiatives such as the ENCODE project. There is an urgent need for well-powered genome-wide studies of the regulation of gene expression and epigenetic mechanisms in the endometrium and other reproductive tissues. These system genetics and genomics studies are critical to decoding GWAS signals, but will also provide insights into gene regulation influencing other reproductive functions including implantation.
Successful GWAS in endometriosis represents an important first step toward discovery of target genes and pathways responsible for increased risk of endometriosis. To capitalize on these results, follow-up studies will require a range of skills combining genetics, genomics, cell biology, functional biology, and clinical research to eventually translate these results into clinical outcomes. Combining gene expression and methylation with genome-wide SNP data can help identify genetic regulation of gene expression and the role of GWAS hits. Studies will need to be designed with sufficient power and combine genetic and functional biology to determine how these GWAS hits affect endometriosis risk. This will not be done by a single group but will require the efforts of many with the requisite skills and reagents. In this respect, using standardized instruments and protocols for collection of phenotypic data and biological specimens [102] [103] [104] [105] will help international collaborations to develop large datasets with sufficient power [75] to first determine the key target genes.
